TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression
- PMID: 33723872
- DOI: 10.1002/em.22432
TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression
Abstract
The T-cell immunoglobulin and mucin domain containing molecule 3 (TIM-3), a crucial immune regulatory molecule, is an emerging immune checkpoint target for cancer therapy. Our study aimed to investigate the association between TIM-3 polymorphisms (rs10053538 C > A, rs10515746 C > A, and rs1036199 A > C) and the susceptibility and prognosis of esophageal squamous cell carcinoma (ESCC). We further detect the effects of polymorphisms on TIM-3 expression. Two independent case-control sets (population-based and hospital-based sets) were performed in total 994 ESCC patients and 998 controls. TIM-3 polymorphisms were genotyped by polymerase chain reaction-ligase detection reaction (PCR). Survival data were available for 198 patients who received platinum-based chemotherapy after surgery. The regulation on TIM-3 expression by the polymorphisms was investigated in 35 patients using real-time quantitative PCR. The association between mRNA level of TIM-3 and survival was detected by using Kaplan-Meier plotter database. We found that for rs10053538 C > A polymorphisms, A allele was associated with significant increased risk of ESCC (odds ratios [OR] = 1.34, 95%CI = 1.05-1.72), and CA/AA genotypes enhanced susceptibility to ESCC for smokers (adjusted OR = 1.61, 95%CI = 1.00-2.59). The patients with AA genotypes had significantly poor prognosis (adjusted HR = 4.98, 95%CI = 1.14-21.71). The patients carrying CA/AA genotypes had significantly higher mRNA levels of TIM-3 than those carrying the CC genotype. Furthermore, high mRNA level of TIM-3 had a shorter overall survival in patients (HR = 2.56, 95%CI = 1.04-6.28). For rs10515746 C > A and rs1036199 A > C polymorphisms, there were no statistical correlation with the progression of ESCC. These data demonstrate that rs10053538 C > A polymorphisms may be associated with the susceptibility and prognosis of ESCC patients through regulating expression of TIM-3.
Keywords: TIM-3; esophageal squamous cell carcinoma; gene expression; polymorphisms; prognosis; risk.
© 2021 Environmental Mutagen Society.
Similar articles
-
Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.Gynecol Oncol. 2020 Oct;159(1):270-276. doi: 10.1016/j.ygyno.2020.07.012. Epub 2020 Jul 19. Gynecol Oncol. 2020. PMID: 32694063
-
The TIM-3 Rs10053538 Polymorphism Is Associated with Clinical Prognosis of Colorectal Cancer.Immunol Invest. 2022 Jul;51(5):1302-1312. doi: 10.1080/08820139.2021.1936011. Epub 2021 Jun 3. Immunol Invest. 2022. PMID: 34080945
-
PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.Asian Pac J Cancer Prev. 2020 Oct 1;21(10):2987-2992. doi: 10.31557/APJCP.2020.21.10.2987. Asian Pac J Cancer Prev. 2020. PMID: 33112558 Free PMC article.
-
TIM family gene polymorphism and susceptibility to rheumatoid arthritis: Systematic review and meta-analysis.PLoS One. 2019 Feb 7;14(2):e0211146. doi: 10.1371/journal.pone.0211146. eCollection 2019. PLoS One. 2019. PMID: 30730912 Free PMC article.
-
Single Nucleotide Polymorphisms (SNPs) in the Shadows: Uncovering their Function in Non-Coding Region of Esophageal Cancer.Curr Pharm Biotechnol. 2024;25(15):1915-1938. doi: 10.2174/0113892010265004231116092802. Curr Pharm Biotechnol. 2024. PMID: 38310451 Review.
Cited by
-
Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy.Front Genet. 2022 Aug 23;13:972664. doi: 10.3389/fgene.2022.972664. eCollection 2022. Front Genet. 2022. PMID: 36081997 Free PMC article.
-
The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review.Cancers (Basel). 2023 Nov 1;15(21):5252. doi: 10.3390/cancers15215252. Cancers (Basel). 2023. PMID: 37958425 Free PMC article. Review.
References
REFERENCES
-
- Anderson, D.E. (2007) TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opinion on Therapeutic Targets, 11, 1005-1009.
-
- Bai, J., Li, X., Tong, D., Shi, W., Song, H. and Li, Q. (2013) T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumor Biology, 34, 805-809.
-
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
-
- Cao, B., Zhu, L., Zhu, S., Li, D., Zhang, C., Xu, C. and Zhang, S. (2010) Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer. Cancer Immunology, Immunotherapy, 59, 1851-1857.
-
- Cao, Y., Zhou, X., Huang, X., Li, Q., Gao, L., Jiang, L., Huang, M. and Zhou, J. (2013) Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One, 8, e53834.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials